Managing Asbestos Liability in Talc Cosmetics Following FDA’s Rule Withdrawal

The Regulatory Gap Created by MoCRA's Unfinished Rulemaking

The Modernization of Cosmetics Regulation Act of 2022 (MoCRA) directed the FDA to establish standardized testing methods for detecting asbestos and other contaminants in talc-containing cosmetic products. The agency's initial proposed approach—anchored heavily in X-ray diffraction (XRD) and transmission electron microscopy (TEM) protocols—drew significant industry and scientific pushback over methodological consistency, detection thresholds, and reproducibility across laboratories.

FDA's decision to withdraw that initial framework and push finalized standardized methods into 2026 has left cosmetic brands, contract manufacturers, and raw talc suppliers in an uncomfortable position. MoCRA's underlying statutory mandate remains in force. FDA retains full adulteration enforcement authority under the Federal Food, Drug, and Cosmetic Act. What is missing is the promised regulatory certainty about which testing methodology will satisfy compliance obligations.

This is not a compliance holiday. It is a compliance vacuum—and vacuums are precisely where litigation risk accumulates fastest.

Why the Vacuum Is More Dangerous Than a Defined Rule

In the absence of a finalized FDA testing standard, three distinct forces are converging on companies in the talc supply chain:

• State tort litigation continues unabated. Plaintiffs' counsel in talc-related mesothelioma and ovarian cancer litigation are not waiting for FDA finality. They are actively arguing that the absence of a federal standard does not excuse manufacturers from adopting the most rigorous scientifically available detection methods.
• FDA adulteration authority remains fully active. Section 601 of the FD&C Act's adulteration provisions do not require a finalized MoCRA testing rule to support an enforcement action. FDA can still pursue adulteration findings based on contamination detected through any scientifically valid method.
• Insurers and downstream retailers are tightening their own diligence requirements. Many national retailers now require supplier attestations regarding asbestos testing protocols independent of what FDA ultimately finalizes.

Companies that interpret the rule withdrawal as a reason to delay testing investment are misreading the risk landscape. The absence of a bright-line federal rule shifts the evidentiary burden toward whatever protocol a company can defend in litigation or before FDA investigators—today.

The Case for Dual-Microscopy Protocols Now

Given this uncertainty, sophisticated cosmetic companies and talc suppliers should not wait for the 2026 standardized methods to be finalized. The most defensible interim posture is voluntary adoption of a dual-microscopy testing protocol combining:

• Polarized Light Microscopy (PLM) for initial screening and bulk mineral identification, and
• Transmission Electron Microscopy (TEM), supplemented where appropriate by energy-dispersive X-ray spectroscopy (EDS), for definitive fiber-level confirmation at sub-micron detection thresholds.

This combined approach mirrors methodologies that have already withstood scrutiny in prior talc litigation and aligns closely with the direction FDA's own scientific advisors signaled before the rule's withdrawal. Adopting a dual-microscopy standard now accomplishes three strategic objectives:

1. It creates a defensible paper trail. In future adulteration inquiries or tort litigation, demonstrating adherence to a scientifically rigorous, multi-method testing regime is far stronger evidence of due care than reliance on a single, lower-sensitivity method.
2. It anticipates the direction of the eventual FDA rule. Companies that build dual-microscopy testing into their quality systems now will face minimal disruption when FDA finalizes its 2026 standard, whatever its precise contours.
3. It signals good faith to regulators and juries alike. Voluntary adoption of heightened testing in the absence of a mandate is a powerful narrative in both regulatory and litigation contexts.

Practical Steps for Brands and Suppliers

Companies should treat this interim period as an opportunity to get ahead of the eventual rule rather than a reason to defer investment. Recommended immediate actions include:

• Audit current supplier testing documentation to determine whether existing protocols rely solely on XRD or lower-sensitivity methods.
• Negotiate supply agreements that contractually require dual-microscopy testing and corresponding chain-of-custody documentation for all talc lots.
• Update internal quality manuals and SOPs to reflect voluntary adoption of the dual-microscopy standard, with clear retention policies for testing records.
• Coordinate with outside counsel to ensure testing documentation is structured to support litigation defense, not merely regulatory filing.
• Monitor FDA's rulemaking docket closely through 2025 and into 2026, as interim guidance documents may signal the agency's evolving preferred methodology before the final rule issues.

The Litigation Risk Calculus

Plaintiffs' firms have shown no hesitation in framing the absence of a finalized federal standard as evidence of industry-wide negligence rather than regulatory ambiguity. Companies that can demonstrate voluntary, scientifically current testing practices are far better positioned to rebut that framing than those that point to regulatory delay as an excuse for inaction.

The prudent posture is not to wait for FDA to tell the industry what is required. It is to adopt the most defensible available protocol now, document it rigorously, and treat the 2026 rulemaking as a floor rather than a starting point.

Conclusion

FDA's withdrawal of its initial MoCRA talc-testing rule does not pause liability exposure—it redistributes it. Cosmetic brands and raw material suppliers that move proactively to dual-microscopy testing protocols will be far better positioned to withstand both regulatory scrutiny and state tort litigation than those that treat the compliance vacuum as a reprieve.